Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions
Author:
Affiliation:
1. Department of Haematology; University Hospital Hotel-Dieu; Nantes France
2. Amgen (Europe) GmbH; Zug Switzerland
Funder
Kim Allcott of Oxford PharmaGenesis
Amgen
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14780/fullpdf
Reference93 articles.
1. Phase 1, open-label, dose escalation study of I-131-CLR1404 in patients with relapsed or refractory multiple myeloma (RRMM);Ailawadhi;Blood,2016
2. Clinically relevant end points and new drug approvals for myeloma;Anderson;Leukemia,2008
3. A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039);Ansell;Blood,2016
4. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma;Arnulf;Haematologica,2012
5. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone;Avet-Loiseau;Leukemia,2010
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances in dual-targeting inhibitors of HDAC6 for cancer treatment;European Journal of Medicinal Chemistry;2024-09
2. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy;Frontiers in Bioscience-Landmark;2024-06-17
3. Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment;Pharmaceuticals;2023-11-19
4. A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure;Clinical Lymphoma Myeloma and Leukemia;2023-11
5. Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma;Cancers;2023-02-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3